Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 80

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 80
---
 program and provide for
working capital and other general corporate purposes. However, our use of these proceeds may differ substantially from our current plans.
If we do not invest or apply the proceeds of this offering in ways that improve our operating results, we may fail to achieve expected
financial results, which could cause our share price to decline.

<div align='center'>51</div>

New investors purchasing our securities will experience immediate and substantial dilution.

Our initial public offering
price is substantially higher than the book value per share of our Ordinary Shares. If you purchase securities in this offering, you
will incur immediate dilution of $9.74 in net tangible book value per Ordinary Shares, based on an assumed initial public offering price
of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus. In addition, the
number of shares available for issuance under our stock option plans will increase annually without further shareholder approval. Investors
will incur additional dilution upon the exercise of stock options. See “Dilution” for more information.

As a result of the shutdown of the federal government, we have determined to rely on Section 8(a) of the Securities Act to cause the registration statement of which this prospectus forms a part to become effective automatically. Our reliance on Section 8(a) could result in a number of potential adverse consequences, including the need for us to file a post-effective amendment and distribute an updated prospectus to investors, or a stop order issued preventing use of the registration statement, and a corresponding substantial share price decline, litigation, reputational harm or other negative results.

The registration statement
of which this prospectus forms a part is expected to become automatically effective by operation of Section 8(a) of the Securities
Act on the 20th calendar day after the most recent amendment of the registration statement filed with the SEC, in lieu of the SEC declaring
the registration statement effective following the completion of its review. Although our reliance on Section 8(a) does not relieve
us and other parties from the responsibility for the adequacy and accuracy of the disclosure set forth in the registration statement
and for ensuring that the registration statement complies with applicable requirements, use of Section 8(a) poses a risk that, after
the date of this prospectus, we may be required to file a post-effective amendment to the registration statement and distribute an updated
prospectus to investors, or otherwise abandon this offering, if changes to the information in